<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DCE508CA-70B7-43EC-99A2-3197E0AA3077"><gtr:id>DCE508CA-70B7-43EC-99A2-3197E0AA3077</gtr:id><gtr:name>Ono Pharmaceutical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A56B73A6-2F90-418C-A6B9-69F9C6CFBE57"><gtr:id>A56B73A6-2F90-418C-A6B9-69F9C6CFBE57</gtr:id><gtr:name>SLA Pharma AG</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DCE508CA-70B7-43EC-99A2-3197E0AA3077"><gtr:id>DCE508CA-70B7-43EC-99A2-3197E0AA3077</gtr:id><gtr:name>Ono Pharmaceutical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A56B73A6-2F90-418C-A6B9-69F9C6CFBE57"><gtr:id>A56B73A6-2F90-418C-A6B9-69F9C6CFBE57</gtr:id><gtr:name>SLA Pharma AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/12BDE253-AA20-4608-BEEB-DA3B9815F3C2"><gtr:id>12BDE253-AA20-4608-BEEB-DA3B9815F3C2</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Hull</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F146"><gtr:id>D97EABF4-74AF-44AD-9C65-6FB31ACFA811</gtr:id><gtr:title>MOLECULAR TARGETS FOR COLORECTAL CANCER CHEMOPREVENTION</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/146</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-03-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>956114</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>SLA Pharma AG</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>The anti-colorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid</gtr:description><gtr:id>9EC6F479-BE35-4B38-9B71-B1F6395EFA3B</gtr:id><gtr:impact>Gut 2010;59:918-25 Phase III RCT
Neoplasia 2010;12:618-27 cell biology of EPA activity
Br J Pharmacol 2012;166:1724-37 pre-clinical efficacy of EPA against CRC liver metastasis</gtr:impact><gtr:outcomeId>02D104ADE64-1</gtr:outcomeId><gtr:partnerContribution>post-doc support and supply of EPA for clinical and pre-clinical studies</gtr:partnerContribution><gtr:piContribution>I was PI on RCT and my lab has performed work to understand the mechanistic basis of the anti-cancer activity of EPA. This collaboration continued with further post-doc support and supply of EPA for clinical and pre-clinical studies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SLA Pharma AG</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>The anti-colorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid</gtr:description><gtr:id>A2E637FB-2483-4403-A444-A1916487E90F</gtr:id><gtr:impact>Gut 2010;59:918-25 Phase III RCT
Neoplasia 2010;12:618-27 cell biology of EPA activity
Br J Pharmacol 2012;166:1724-37 pre-clinical efficacy of EPA against CRC liver metastasis</gtr:impact><gtr:outcomeId>02D104ADE64-2</gtr:outcomeId><gtr:partnerContribution>post-doc support and supply of EPA for clinical and pre-clinical studies</gtr:partnerContribution><gtr:piContribution>I was PI on RCT and my lab has performed work to understand the mechanistic basis of the anti-cancer activity of EPA. This collaboration continued with further post-doc support and supply of EPA for clinical and pre-clinical studies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ono Pharmaceutical</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>AE3-208</gtr:description><gtr:id>2235DB87-54E7-40FF-A36A-23D03734197E</gtr:id><gtr:impact>pharmacological inhibition of PGE2-EP4 receptor signalling (essential for Oncogene publication)</gtr:impact><gtr:outcomeId>DB6F6126961-1</gtr:outcomeId><gtr:partnerContribution>drug supply</gtr:partnerContribution><gtr:piContribution>cell studies with this EP4 receptor antagonist</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>local radio</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>77395498-718D-4D01-95C9-455E2847AA81</gtr:id><gtr:impact>radio interview 3-5 mins

don't know</gtr:impact><gtr:outcomeId>FEBE2459402</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>newspaper article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>A99D3414-76C3-4EE2-9C44-A1184AB28865</gtr:id><gtr:impact>small article on research area

not sure</gtr:impact><gtr:outcomeId>8325A18228A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>You and your Guts University public showcase</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>8014814E-871B-4DD7-BEE1-3AD9A7E562BA</gtr:id><gtr:impact>day meeting for public dissemination of University activities

not sure</gtr:impact><gtr:outcomeId>C3BFC690D92</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>218500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>2BE9F74A-0B77-48D4-900A-46F80B408CA3</gtr:id><gtr:outcomeId>LHhTmdrp4xe</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1186907</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EME Programme</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A4C00B7A-DBC7-4291-ACA6-67E49C47C34C</gtr:id><gtr:outcomeId>XEvetoB7CA60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>228454</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:fundingRef>L381</gtr:fundingRef><gtr:id>56D36088-98B1-45F6-B568-BF05857232F5</gtr:id><gtr:outcomeId>56d6c7056c6387.17118376</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Awareness and Early Diagnosis Initiative</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>861CF356-C82B-4571-B920-4E1C6C9014C2</gtr:id><gtr:outcomeId>TzWua1fEzWv</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>stable transfectant of HT-29 human colorectal cancer cell line expressing EP4 receptor</gtr:description><gtr:id>8C153D02-FBA8-4B66-B0AC-F1A5D90FCD08</gtr:id><gtr:impact>unknown</gtr:impact><gtr:outcomeId>09F50CD2FF1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HT-29-EP4 human CRC cells</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3FFE25A1-0BD8-4E5B-91C0-D6949B8BA685</gtr:id><gtr:title>Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>4BA99143723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52D3F17D-35D2-4408-B0A3-BC5BF18F5B9D</gtr:id><gtr:title>FGFR1-induced epithelial to mesenchymal transition through MAPK/PLC?/COX-2-mediated mechanisms.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/217f31ab8f4f4ea63a8443ea8ca722d0"><gtr:id>217f31ab8f4f4ea63a8443ea8ca722d0</gtr:id><gtr:otherNames>Tomlinson DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12568_28_22701738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F2D09F1-9AB2-4A0E-B4B8-C07D6598D653</gtr:id><gtr:title>Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4c341f0f0afa0444a8c7a1c105092d1"><gtr:id>a4c341f0f0afa0444a8c7a1c105092d1</gtr:id><gtr:otherNames>West NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_12568_28_20348368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11F3B965-175F-4456-8EEF-5BB39131203D</gtr:id><gtr:title>Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and roux-en-Y gastric bypass.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff7138d95a6c0acc2117917b0b45fbad"><gtr:id>ff7138d95a6c0acc2117917b0b45fbad</gtr:id><gtr:otherNames>Sainsbury A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>5124E90FC46</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BAB811B-CF1C-4D7A-BF9E-AD4409375801</gtr:id><gtr:title>Aspirin in the chemoprevention of colorectal neoplasia: an overview.</gtr:title><gtr:parentPublicationTitle>Cancer prevention research (Philadelphia, Pa.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfebd6873617c72013957d09cfca8dff"><gtr:id>dfebd6873617c72013957d09cfca8dff</gtr:id><gtr:otherNames>Chan AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1940-6215</gtr:issn><gtr:outcomeId>pm_12568_28_22084361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B58BEED4-C993-43F2-826B-7BFBD6B27CCB</gtr:id><gtr:title>Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3fed3eff24cf6809582125e38eee86f"><gtr:id>d3fed3eff24cf6809582125e38eee86f</gtr:id><gtr:otherNames>Hawcroft G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>23F99019232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D195ED8-83BE-46FB-8420-394F4E1BC730</gtr:id><gtr:title>Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.</gtr:title><gtr:parentPublicationTitle>Neoplasia (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3fed3eff24cf6809582125e38eee86f"><gtr:id>d3fed3eff24cf6809582125e38eee86f</gtr:id><gtr:otherNames>Hawcroft G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-5586</gtr:issn><gtr:outcomeId>pm_12568_28_20689756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7A6B9EA-4F98-4C9B-8E0C-40AA6591A2CA</gtr:id><gtr:title>Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e9315464f6e3ba1a904706414f2abbd"><gtr:id>3e9315464f6e3ba1a904706414f2abbd</gtr:id><gtr:otherNames>Piazzi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>5453a47593ed93.05103862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7010E029-B258-4E3F-A192-5C1080032A63</gtr:id><gtr:title>Altered intestinal epithelium-associated lymphocyte repertoires and function in ApcMin/+ mice.</gtr:title><gtr:parentPublicationTitle>International journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9c7e985a4638fe1b6e5d88ae013ed20"><gtr:id>d9c7e985a4638fe1b6e5d88ae013ed20</gtr:id><gtr:otherNames>Marsh L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1019-6439</gtr:issn><gtr:outcomeId>pm_12568_28_21879254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3130478-3EA1-4B0C-9669-A568B09B0CCC</gtr:id><gtr:title>Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8d8fa93fd754f5d7048f4b62353e9c5"><gtr:id>a8d8fa93fd754f5d7048f4b62353e9c5</gtr:id><gtr:otherNames>Chalmers CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>BC709F353D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BACB3C83-CCDA-4A3E-B90E-39EF5F204C4F</gtr:id><gtr:title>Nutritional agents with anti-inflammatory properties in chemoprevention of colorectal neoplasia.</gtr:title><gtr:parentPublicationTitle>Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0080-0015</gtr:issn><gtr:outcomeId>pm_12568_28_22893204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10C90A59-F1DA-4103-B549-BB612E63FDDC</gtr:id><gtr:title>A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f13b1621a3cfc3cea05b8090aaf99c6"><gtr:id>0f13b1621a3cfc3cea05b8090aaf99c6</gtr:id><gtr:otherNames>Watson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5aa517929389a4.42728614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43ACC504-D2B0-4B5A-9959-876BDEA6B8AD</gtr:id><gtr:title>Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing?</gtr:title><gtr:parentPublicationTitle>Digestion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4108e7488c6ac8a702b8365559fc716e"><gtr:id>4108e7488c6ac8a702b8365559fc716e</gtr:id><gtr:otherNames>Lee TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-2823</gtr:issn><gtr:outcomeId>pm_12568_28_22538301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4598CCB8-8226-4BED-88CB-2163705BAC67</gtr:id><gtr:title>A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apc?14/+ mice.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be667b3bec8ad432238962f345d6883d"><gtr:id>be667b3bec8ad432238962f345d6883d</gtr:id><gtr:otherNames>Nakanishi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>5aa517b650fc56.63725901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C12B2748-EA84-4BE2-9810-7A379547A126</gtr:id><gtr:title>Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8d8fa93fd754f5d7048f4b62353e9c5"><gtr:id>a8d8fa93fd754f5d7048f4b62353e9c5</gtr:id><gtr:otherNames>Chalmers CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>6B16219FD63</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23198640-E4B9-4C97-B496-A7161B4ED1EF</gtr:id><gtr:title>Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/764c41ae6c4f674a66fec7309e3f2fb9"><gtr:id>764c41ae6c4f674a66fec7309e3f2fb9</gtr:id><gtr:otherNames>Cockbain AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5453a50fb505e5.44721589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>339F80D0-153D-45E9-A66D-AC2E68E7F838</gtr:id><gtr:title>Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a07c9b961f080992960bfd3742085432"><gtr:id>a07c9b961f080992960bfd3742085432</gtr:id><gtr:otherNames>Walsh E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58bfccd0922d27.93282355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>628A303A-1D92-41FB-BE5F-B17641EEEC13</gtr:id><gtr:title>The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3fed3eff24cf6809582125e38eee86f"><gtr:id>d3fed3eff24cf6809582125e38eee86f</gtr:id><gtr:otherNames>Hawcroft G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>pm_12568_28_22300262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48B7AF78-0512-4635-9DC5-951AA23375E2</gtr:id><gtr:title>Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0808a294aedf6927e0ef608274dc8c37"><gtr:id>0808a294aedf6927e0ef608274dc8c37</gtr:id><gtr:otherNames>Burr NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0192-0790</gtr:issn><gtr:outcomeId>56d6c3c58dcf45.19436327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6580E2D9-A7FA-4C4F-AB9F-073577377CE3</gtr:id><gtr:title>Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c59835b27395f668dc48a4dd07b201e"><gtr:id>7c59835b27395f668dc48a4dd07b201e</gtr:id><gtr:otherNames>Kant P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>pm_12568_28_21386810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A2C7F41-B35D-4660-B8E5-FD3E54775D86</gtr:id><gtr:title>Omega-3 polyunsaturated fatty acids.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1521-6918</gtr:issn><gtr:outcomeId>pm_12568_28_22122770</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23470614-4A91-46C1-A275-2D27B9EB1B0F</gtr:id><gtr:title>Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/764c41ae6c4f674a66fec7309e3f2fb9"><gtr:id>764c41ae6c4f674a66fec7309e3f2fb9</gtr:id><gtr:otherNames>Cockbain AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_12568_28_21490374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>345AF0E3-2FA5-4B70-B375-173D70F0FEE8</gtr:id><gtr:title>Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apcmouse model of intestinal tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa5176617b465.61620214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABF060D1-3040-4810-8D0D-529FD4C794AD</gtr:id><gtr:title>Rectal epithelial cell mitosis and expression of macrophage migration inhibitory factor are increased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid obesity: implications for long-term neoplastic risk following RYGB.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c59835b27395f668dc48a4dd07b201e"><gtr:id>7c59835b27395f668dc48a4dd07b201e</gtr:id><gtr:otherNames>Kant P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_12568_28_21303912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FDBDD54-87A3-41AA-B51F-810A9DD5196F</gtr:id><gtr:title>Lack of interleukin-4 receptor alpha chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b91e679a41d6a94802fa8b310e6ce6"><gtr:id>76b91e679a41d6a94802fa8b310e6ce6</gtr:id><gtr:otherNames>Ko CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>83B773B7606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01355866-3166-40A7-992D-F5811C61EDC0</gtr:id><gtr:title>The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cd4712a36398da9664c8069020abb7e"><gtr:id>9cd4712a36398da9664c8069020abb7e</gtr:id><gtr:otherNames>Scaioli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d6c3c4e0c043.01713001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>283DCD88-E664-4010-BA2C-616B127F8247</gtr:id><gtr:title>Macrophage migration inhibitory factor promotes intestinal tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5A57DD61E83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EACE8123-DDC8-4064-947D-61F1B384280F</gtr:id><gtr:title>Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49eebf384e31b7723c692128e667da67"><gtr:id>49eebf384e31b7723c692128e667da67</gtr:id><gtr:otherNames>Cuthbert RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>06B3572A925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13FC6112-385B-47DD-B4FD-EC8775A27A92</gtr:id><gtr:title>Faecal calprotectin levels before and after weight loss in obese and overweight subjects.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c59835b27395f668dc48a4dd07b201e"><gtr:id>7c59835b27395f668dc48a4dd07b201e</gtr:id><gtr:otherNames>Kant P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>pm_12568_28_22410961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07C829B9-6F1F-4C5B-B5C4-7FB06ADA4135</gtr:id><gtr:title>Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>74AE127296F</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/146</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>